NAD+ Administration Methods: Subcutaneous NAD+, IV NAD+ and NMN Capsules Compared

Interest in NAD+ has expanded from basic cellular research into oral supplements, intravenous infusions and experimental injectable preparations.

The three methods most frequently discussed are:

1. Subcutaneous NAD+, often abbreviated to SubQ NAD+
2. Intravenous NAD+, commonly called an NAD+ IV infusion
3. Oral NAD+ precursors, particularly NMN capsules

Although all three approaches are intended to influence NAD+ metabolism, they are not equivalent.

They deliver different compounds through different routes, have different levels of human evidence and introduce substantially different safety and regulatory considerations.

The most important distinction is that NMN capsules provide a precursor the body can use to produce NAD+. Subcutaneous and intravenous methods attempt to administer NAD+ itself.

This guide compares NAD+ SubQ injections, IV NAD+ therapy and oral NMN capsules, including how each method works, why each route is studied and what the available evidence actually supports. For the underlying biology—how NAD+ supports cellular energy, mitochondria, sirtuins and DNA repair—see our detailed guide to NAD+, mitochondrial function and ageing.

NAD+ administration methods at a glance

Method	What is administered?	Evidence level	Principal research use
Oral NMN capsules	An NAD+ precursor	Moderate human research	Longer-term NAD+ precursor and metabolic studies
IV NAD+ infusion	NAD+ directly into a vein	Limited human research	Supervised pharmacokinetic and condition-specific research
Subcutaneous NAD+	NAD+ beneath the skin	Very limited evidence	Experimental administration research
Oral NR capsules	An NAD+ precursor	Moderate human research	NAD+ metabolite and precursor studies
Oral NAD+	NAD+ through digestion	Limited comparative evidence	Supplement and absorption research

These evidence ratings do not mean NMN is a proven treatment. They indicate that oral NMN has been investigated in more controlled human studies than injectable NAD+ for general wellness or longevity.

Why are there different ways to influence NAD+?

NAD+ is involved in cellular energy metabolism, mitochondrial respiration, DNA repair, sirtuin activity and many other biological processes.

However, delivering more NAD+ to the body is not as simple as placing the molecule into the bloodstream or digestive system.

Researchers must consider:

• How the compound is absorbed
• Whether it remains intact
• How quickly it is metabolised
• Which tissues receive it
• Whether it reaches the inside of cells
• Whether it enters the cytoplasm, nucleus or mitochondria
• How long changes in NAD+ metabolism persist
• Whether higher blood NAD+ produces a useful clinical outcome

A route that causes rapid systemic exposure is not automatically better than one that acts gradually. A measurable increase in blood NAD+ is also not proof that NAD+ has increased in every tissue.

Method 1: Oral NMN capsules

What is NMN?

NMN stands for nicotinamide mononucleotide.

It is not identical to NAD+. NMN is an intermediate that the body can convert into NAD+ through enzymes known as nicotinamide mononucleotide adenylyltransferases.

NMN also forms part of the salvage pathway—the recycling system cells use to maintain NAD+ availability.

When an NMN capsule is swallowed, the compound enters the digestive system. NMN and its metabolites may then be absorbed and used in NAD+ biosynthetic pathways.

The exact contribution of intact NMN, nicotinamide riboside and other breakdown products may vary according to the tissue and biological context.

Why are NMN capsules used in research?

Oral NMN is principally investigated because it offers a non-invasive way to alter NAD+-related metabolism over days or weeks.

Research applications include studying:

• Blood NAD+ and related metabolites
• Glucose metabolism
• Insulin sensitivity
• Skeletal-muscle function
• Physical performance
• Fatigue
• Cardiometabolic markers
• Healthy-ageing biology
• Mitochondrial disorders
• NAD+ metabolism during illness

Oral administration is also easier to blind against placebo in a clinical trial than an injection or several-hour infusion.

What does human NMN research show?

Controlled human studies generally suggest that oral NMN can alter NAD+-related metabolites and is reasonably well tolerated over the short periods studied.

A 2021 randomised controlled trial investigated NMN in postmenopausal women with prediabetes who were overweight or obese.

After ten weeks, the NMN group showed improvements in insulin-stimulated glucose disposal and skeletal-muscle insulin signalling compared with placebo.

The study was small and involved a specific population. It did not prove that NMN:

• Causes weight loss
• Prevents diabetes
• Extends lifespan
• Reverses ageing
• Improves energy in everyone
• Produces the same result in healthy adults

Another randomised study involving 80 healthy middle-aged adults found that oral NMN increased blood NAD+ concentrations. Some physical-function outcomes were also explored, but findings from individual trials require replication before broad conclusions can be drawn.

A 2025 hospital study found that an oral pharmaceutical NMN formulation increased blood NAD+ in people with COVID-19 and acute kidney injury. It did not significantly improve markers of kidney injury, inflammation or disease severity.

This illustrates an important distinction: raising a biomarker is easier to demonstrate than improving a clinical outcome.

Potential research use cases for NMN capsules

Oral NMN may be selected in research when the objective is to:

• Study gradual changes in NAD+ metabolism
• Investigate repeated daily precursor exposure
• Conduct placebo-controlled trials
• Avoid invasive administration
• Monitor effects over several weeks or months
• Examine metabolic or physical-function outcomes
• Compare different NAD+ precursors
• Study a scalable oral intervention

These are research-design considerations, not personal treatment recommendations.

Advantages of NMN capsules

• Non-invasive
• Convenient for longer studies
• Easier to compare with placebo
• More human trials than SubQ NAD+
• Does not require venous access
• Lower infection risk than injectable routes
• Allows repeated exposure without a clinical procedure

Limitations of NMN capsules

• NMN must pass through digestion and metabolism
• Blood changes may not reflect every tissue
• Product quality can vary
• Optimal human use has not been established
• Long-term safety evidence remains limited
• Clinical outcomes have been inconsistent
• It is not proven to extend human lifespan

When would oral NMN make the most scientific sense?

Of the three methods, oral NMN is generally the most logical option for a non-invasive human study investigating whether sustained precursor intake changes NAD+ biomarkers or defined metabolic outcomes.

It is not necessarily the best method for every research question, but it has a more developed evidence base and a more favourable practical risk profile than experimental NAD+ injections.

Method 2: Intravenous NAD+ infusion

What is IV NAD+?

An NAD+ IV infusion delivers a prepared NAD+ solution directly into a vein.

This bypasses the digestive system and places NAD+ into the bloodstream. However, it does not guarantee that intact NAD+ immediately enters every cell or mitochondrion.

Extracellular NAD+ may be:

• Broken down by extracellular enzymes
• Converted into smaller NAD+ metabolites
• Cleared from circulation
• Taken up or processed differently between tissues
• Used in extracellular signalling pathways

The subsequent biological pathway remains an active area of research.

Why is NAD+ administered intravenously?

The scientific reason to use an intravenous route is to control systemic exposure more directly than oral administration allows.

IV administration may be used in research to examine:

• NAD+ pharmacokinetics
• Plasma and urine metabolites
• Immediate systemic responses
• Metabolic processing of extracellular NAD+
• Condition-specific adjunctive treatment
• Whether faster NAD+ exposure affects a clinical endpoint

The commercial wellness industry also promotes NAD+ IV infusions for energy, cognition, recovery, addiction support and anti-ageing.

These broad wellness claims are not supported by large, high-quality randomised clinical trials.

What does IV NAD+ research show?

A frequently cited 2019 pilot study administered an NAD+ infusion over six hours to 11 healthy men.

The investigators measured NAD+ and related metabolites in blood and urine.

During the first two hours, plasma NAD+ did not rise substantially despite continuous infusion. This suggested that administered NAD+ was being rapidly removed, metabolised or taken up.

Changes in NAD+ and related metabolites appeared later in the infusion.

The study was useful for understanding the possible metabolic fate of IV NAD+, but it was:

• Small
• Not placebo-controlled
• Limited to healthy men
• Designed around pharmacokinetics
• Not designed to assess anti-ageing benefits
• Not designed to assess energy or cognition

It therefore cannot establish that NAD+ IV therapy improves fatigue, brain function, addiction recovery or longevity.

A 2025 study also investigated NAD+ as part of treatment for sudden sensorineural hearing loss. The condition-specific findings require independent replication and should not be generalised to routine NAD+ wellness infusions.

Potential research and clinical use cases for IV NAD+

An intravenous route might be chosen when researchers need:

• Precisely supervised administration
• Direct access to systemic circulation
• Frequent blood sampling during administration
• Pharmacokinetic measurements
• Careful observation of immediate reactions
• A controlled hospital or research environment
• Investigation of a specific medical condition

IV NAD+ should not be chosen merely because “direct to the bloodstream” sounds more powerful.

Clinical value must be demonstrated through meaningful outcomes, not assumed from the route.

Advantages of IV NAD+

• Avoids gastrointestinal absorption
• Allows controlled administration
• Enables real-time clinical observation
• Suitable for pharmacokinetic research
• Allows serial blood sampling
• Can be stopped if an immediate reaction occurs

Limitations of IV NAD+

• Requires venous access
• Requires trained clinical supervision
• Can be time-consuming
• Carries infection and vascular risks
• More expensive than oral administration
• Clinical efficacy remains poorly established
• Direct bloodstream delivery does not guarantee cellular or mitochondrial uptake
• Product sterility and endotoxin control are critical

NAD+ infusion reactions

Commercial reports and regulatory warnings describe reactions associated with injectable NAD+ products.

The US FDA has received adverse-event reports involving compounded NAD+ injections, including:

• Severe chills
• Shaking
• Vomiting
• Fatigue
• Reactions requiring medical treatment

Some reactions were considered consistent with excessive endotoxin contamination.

Endotoxins are inflammatory bacterial components that can remain even when living bacteria are absent. Injectable products require strict endotoxin and sterility controls because contamination can produce severe systemic reactions.

This is fundamentally different from taking a contaminated oral capsule: an IV product bypasses many of the body’s protective barriers.

When would IV NAD+ make the most scientific sense?

IV NAD+ is most defensible within a properly governed clinical study investigating pharmacokinetics or a clearly defined medical endpoint.

The current evidence does not support routine IV NAD+ as a proven anti-ageing, energy-enhancing or cognitive treatment.

Method 3: Subcutaneous NAD+

What is SubQ NAD+?

Subcutaneous NAD+, often shortened to SubQ NAD+, refers to NAD+ delivered into the fatty tissue beneath the skin.

This is the same general route used for some approved medicines such as insulin and certain biologic therapies. However, the established safety of the subcutaneous route for those medicines does not establish the safety of subcutaneous NAD+.

Every injectable compound requires its own evidence concerning:

• Absorption
• Bioavailability
• Local tissue compatibility
• Stability
• Sterility
• Concentration
• pH
• Osmolality
• Pharmacokinetics
• Systemic safety

How might SubQ NAD+ differ from IV NAD+?

In general pharmacology, subcutaneous administration can produce slower absorption than direct intravenous delivery.

However, reliable human pharmacokinetic data specifically characterising SubQ NAD+ are lacking.

It should not be assumed that subcutaneous NAD+ creates a predictable “slow release” or produces more stable NAD+ levels. Those claims require direct measurement in controlled studies.

Possible fates include:

• Local breakdown in subcutaneous tissue
• Entry into local capillaries or lymphatic circulation
• Conversion into smaller metabolites
• Variable absorption between individuals
• Local inflammatory or tissue reactions

Without dedicated human studies, the proportion reaching circulation intact and its subsequent biological activity remain uncertain.

Why is SubQ NAD+ discussed?

SubQ NAD+ is generally promoted as a more convenient alternative to a lengthy IV infusion.

Common marketing claims include:

• Easier administration
• Shorter procedure time
• Gradual absorption
• More frequent administration
• Lower cost than IV clinics
• Sustained NAD+ exposure

These are proposed practical advantages—not established clinical benefits.

There is a major gap between saying that a subcutaneous injection is convenient and demonstrating that it safely produces a useful biological effect.

What does the SubQ NAD+ research show?

At present, there is no robust body of published human clinical evidence establishing:

• SubQ NAD+ pharmacokinetics
• SubQ NAD+ bioavailability
• An approved dosage
• An approved administration schedule
• Long-term safety
• Clinical effectiveness
• Superiority to oral NMN
• Superiority to IV NAD+
• Effectiveness for energy, longevity or cognition

This makes SubQ NAD+ the most experimental of the three approaches covered in this comparison.

The absence of evidence does not prove that the route has no biological activity. It means confident efficacy and safety claims cannot currently be made.

Potential legitimate research use cases for SubQ NAD+

Subcutaneous NAD+ could be investigated in a formal study designed to establish:

• Absorption characteristics
• Pharmacokinetics
• Bioavailability
• Local tolerability
• Dose–exposure relationships
• Metabolic breakdown
• Comparison with IV and oral routes
• Whether repeated exposure is feasible

These are questions for controlled research, not established reasons for self-administration.

Potential risks of SubQ NAD+

Subcutaneous administration can introduce risks including:

• Injection-site pain
• Redness
• Swelling
• Bruising
• Inflammation
• Infection
• Abscess formation
• Tissue damage
• Incorrect administration
• Contamination
• Endotoxin exposure
• Unpredictable absorption

A product labelled “research use only” has not necessarily been manufactured, tested or released as a sterile medicine suitable for injection.

A purity result from HPLC does not establish sterility, endotoxin safety, particulate control, correct pH or clinical suitability.

When would SubQ NAD+ make scientific sense?

At present, its clearest legitimate use case would be within an approved study designed to answer basic pharmacokinetic and safety questions.

It cannot currently be recommended as a proven alternative to IV NAD+ or oral NMN.

SubQ vs IV vs NMN capsules: detailed comparison

Consideration	SubQ NAD+	IV NAD+	NMN capsules
Compound	NAD+	NAD+	NAD+ precursor
Route	Beneath the skin	Directly into a vein	Digestive system
Human evidence	Very limited	Limited	Developing/moderate
Pharmacokinetic data	Not established	Small human pilot data	Multiple human studies
Invasiveness	Invasive	More invasive	Non-invasive
Clinical supervision	Necessary	Necessary	Usually not procedural
Sterility requirement	Critical	Critical	Not an injectable
Infection risk	Present	Present	Minimal
Best-supported research use	Early route and safety research	Supervised pharmacokinetic research	Longer-term precursor studies
Proven anti-ageing effect	No	No	No
Proven lifespan extension	No	No	No

Which NAD+ method has the strongest evidence?

For influencing NAD+-related metabolism in humans, oral NMN and oral NR currently have a broader research base than injectable NAD+.

This does not mean oral NMN has been proven to slow ageing. It means researchers have completed more controlled human studies using oral precursors.

IV NAD+ has limited human pharmacokinetic research and some condition-specific investigation. Broad commercial claims remain unsupported.

Subcutaneous NAD+ has the weakest published human evidence and no established general clinical use.

Choosing a route according to the research question

The appropriate research route depends on what investigators are trying to measure.

Use oral NMN research when the objective is:

• Studying sustained precursor exposure
• Monitoring NAD+-related biomarkers over time
• Conducting a placebo-controlled trial
• Minimising procedural burden
• Examining longer-term metabolic outcomes

Use IV NAD+ research when the objective is:

• Studying immediate systemic administration
• Measuring NAD+ pharmacokinetics
• Collecting frequent blood samples
• Closely monitoring acute effects
• Investigating a defined condition in a clinical setting

Investigate SubQ NAD+ when the objective is:

• Establishing whether the route is feasible
• Measuring absorption and bioavailability
• Characterising local tolerability
• Comparing it scientifically with IV or oral routes

These are research applications. They are not personal-use recommendations or administration protocols.

Does faster NAD+ delivery mean better results?

No.

Rapid systemic administration may produce:

• A higher peak concentration
• Faster metabolism
• Greater acute side effects
• More rapid clearance
• No additional clinical benefit

Gradual precursor intake may produce:

• Slower changes in metabolites
• Easier repeated exposure
• Lower procedural risk
• No guaranteed clinical benefit

The most useful route is not necessarily the route with the fastest delivery. It is the route that produces a meaningful outcome with an acceptable risk profile.

No study has established that a rapid rise in circulating NAD+ produces superior longevity, energy or mitochondrial benefits.

Can blood NAD+ confirm mitochondrial improvement?

Not by itself.

Blood NAD+ can be a useful biomarker, but it does not necessarily measure NAD+ inside the mitochondria of:

• Skeletal muscle
• The liver
• The brain
• The heart
• Adipose tissue

A study can demonstrate higher blood NAD+ without demonstrating better mitochondrial ATP production, improved physical performance or a health benefit.

Strong clinical research should combine biochemical measurements with relevant functional or clinical outcomes.

Frequently asked questions

Is SubQ NAD+ better than an NAD+ IV?

There is insufficient human evidence to determine whether SubQ NAD+ is equivalent or superior to IV NAD+. Subcutaneous pharmacokinetics and clinical effectiveness have not been established.

Are NAD+ injections better than NMN capsules?

No reliable evidence shows that injectable NAD+ is generally more effective than oral NMN. The routes affect NAD+ metabolism differently and have not been adequately compared in head-to-head trials.

Why might a researcher choose NMN instead of NAD+?

NMN is a precursor that can be taken orally and has been studied in several human trials. It is more practical for repeated, longer-duration research than an invasive infusion.

Why might IV NAD+ be used?

IV NAD+ may be investigated when researchers require controlled systemic administration, frequent blood sampling and direct observation in a clinical environment.

Why might SubQ NAD+ be studied?

SubQ NAD+ could be studied to determine its absorption, bioavailability, tolerability and feasibility. These properties are not yet adequately established in humans.

Does NAD+ IV work immediately?

IV administration enters the circulation immediately, but this does not mean intact NAD+ immediately enters cells or creates an immediate health benefit. The molecule may be rapidly metabolised.

Are NMN capsules proven to reverse ageing?

No. NMN can influence NAD+-related metabolism, but it has not been proven to reverse human ageing or extend lifespan.

Can NAD+ SubQ injections be self-administered?

There is no established, licensed SubQ NAD+ self-administration protocol. Research-labelled products should not be used for human injection.

Is injectable NAD+ sterile?

Injectable suitability cannot be determined from the name, appearance or HPLC purity alone. Sterility, endotoxin, particulate, identity, concentration and stability testing are separate requirements.

Which NAD+ route is best for longevity?

No NAD+ route has been proven to extend human lifespan. Oral precursors currently have the more developed human research base, but clinically meaningful longevity outcomes remain unproven.

NŪVO Research Perspective

SubQ NAD+, IV NAD+ and oral NMN should not be presented as three interchangeable ways of achieving the same result.

They answer different research questions:

• NMN capsules investigate whether the body can gradually increase NAD+ through precursor metabolism.
• IV NAD+ investigates how directly administered extracellular NAD+ is processed under clinical supervision.
• SubQ NAD+ remains an experimental route requiring foundational human pharmacokinetic and safety research.

The strength of the evidence should determine how confidently each method is described.

For oral NMN, researchers can point to controlled human studies showing changes in NAD+-related metabolism, with limited and inconsistent clinical outcomes.

For IV NAD+, researchers can point to small pharmacokinetic studies, but not broad proof of anti-ageing or wellness benefits.

For SubQ NAD+, the responsible conclusion is that there is not yet enough published human evidence to define its efficacy, pharmacokinetics or general clinical use. Browse the research catalogue — every compound is supplied for laboratory research only.

Research and medical disclaimer

This article is for educational and scientific-information purposes only. It does not provide medical advice, injection instructions, dosing information or a recommendation to administer NAD+, NMN or any research material.

Research-grade products are not medicines and must not be used for human administration. Injectable preparations require pharmaceutical controls extending beyond chemical purity, including sterility, endotoxin, particulate, stability and container-closure testing.

Anyone considering a medically supervised infusion or dietary supplement should consult an appropriately qualified healthcare professional.

Sources and further reading

1. Grant R, et al. A pilot study investigating changes in human plasma and urine NAD+ during a six-hour intravenous infusion. Frontiers in Aging Neuroscience, 2019. View the IV NAD+ study on PubMed
2. Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 2021. View the NMN clinical trial on PubMed
3. Yi L, et al. The efficacy and safety of beta-nicotinamide mononucleotide supplementation in healthy middle-aged adults. 2022. View the randomised trial on PubMed
4. Pencina KM, et al. Oral MIB-626 safely raises blood NAD+ in hospitalised patients with COVID-19 and acute kidney injury. FASEB BioAdvances, 2025. View the randomised trial on PubMed
5. Vinten KT, et al. NAD+ precursor supplementation in human ageing: clinical evidence and challenges. Nature Metabolism, 2025. View the review on PubMed
6. Sun C, et al. Effects of nicotinamide mononucleotide on glucose and lipid metabolism: a systematic review of human randomised trials. 2024. View the systematic review on PubMed
7. Brakedal B, et al. The differential impact of NAD+ boosters in healthy participants. 2026. View the comparative human research on PubMed
8. US Food and Drug Administration. FDA reminds compounders to use ingredients suitable for sterile compounding. 2024. Read the FDA injectable NAD+ safety notice
9. Yaku K, et al. Evaluation of NAD+, NADH and NAD+ precursors across different clinical conditions. 2024. View the systematic review on PubMed